HUTCHMED Highlights Pivotal Phase II Data for Fanregratinib in ICC, NMPA Grants Priority Review for NDA
HCM is trading near its 52-week low of $9.77 (5.1% above the low).
Summary
HUTCHMED presented positive pivotal Phase II data for its cancer drug fanregratinib, which has led to the China NMPA granting priority review for its New Drug Application.
Key Events · Product Development and Regulatory · HCM
-
Pivotal Phase II Data Presented
HUTCHMED highlighted positive results from a pivotal Phase II registration study of fanregratinib in pretreated advanced intrahepatic cholangiocarcinoma (ICC) at the ESMO Gastrointestinal Cancers Congress 2026.
-
Strong Efficacy and Safety Profile
The study achieved an objective response rate (ORR) of 42.5%, a median duration of response (DoR) of 6.9 months, and a median overall survival (OS) of 16.6 months, with a manageable safety profile.
-
NMPA Grants Priority Review for NDA
The China National Medical Products Administration (NMPA) accepted a New Drug Application (NDA) for fanregratinib and granted it priority review in December 2025, based on these pivotal Phase II data.
Analysis · HCM · Life Sciences
HUTCHMED announced strong pivotal Phase II data for fanregratinib in pretreated advanced intrahepatic cholangiocarcinoma (ICC), demonstrating a 42.5% objective response rate and a median overall survival of 16.6 months. This positive data has already led to the China NMPA accepting a New Drug Application (NDA) for fanregratinib with priority review, significantly advancing the drug towards potential market approval in China.
How filings like this one have moved
In the 30 days to Oct 22, 2026, 36.9% of the 1029 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.77%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HCM was trading at $10.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $9.77 to $19.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.